Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways.

Genhong Li,Jingwei Yao,Zhen Lu,Lian Yu,Qinwei Chen,Lihong Ding,Zhihong Fang,Yin Li,Bing Xu

Drugs in R&D（2023）

引用 0|浏览2

暂无评分

摘要

Simvastatin can selectively and effectively eradicate FLT3/ITD AML cells in vitro and in vivo, and its mechanism may be related to the disruption of the HMG-CoA reductase pathway and the downregulation of the MEK/ERK and p38-MAPK signaling pathways.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要